Semaglutide: Difference between revisions

(4 intermediate revisions by the same user not shown)

Line 2:

| generic = Semaglutide

| brand = Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM)

| structure = 31-amino-acid acylated peptide analog of human [[GLP-1]] (7–37), with Aib substitution at position 8 (blocks DPP-4 cleavage) and a C18 fatty diacid linked via γGlu-2×OEG spacer at Lys26 (drives albumin binding → ~165 h half-life)<ref name="lau2015">Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. ''J Med Chem'' 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726</ref>

| structure =

| classes = [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · [[Anti-obesity medicines|Anti-obesity]] · [[Cardiovascular risk reduction]] agent

| mechanism = ~~Selective long~~-acting agonist of the [[GLP-1 receptor]] ~~(class B GPCR)~~. Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and direct cardiovascular and renal protective effects.<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351. doi:10.1016/j.molmet.2021.101351</ref>

| mechanism = Long-acting agonist of the [[GLP-1 receptor]].

| uses = [[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM

| starting_dose = Ozempic: 0.25 mg SC weekly × 4 wk<ref name="ozempic-label">US FDA. ''Ozempic (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s019lbl.pdf</ref> · Wegovy: 0.25 mg SC weekly × 4 wk<ref name="wegovy-label">US FDA. ''Wegovy (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf</ref> · Rybelsus: 3 mg PO daily × 30 d<ref name="rybelsus-label">US FDA. ''Rybelsus (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf</ref>

Line 12:

Line 14:

| onset = Glycemic effect within days;{{Citation needed}} full weight effect over months<ref name="step1">Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). ''NEJM'' 384:989. doi:10.1056/NEJMoa2032183</ref>

| duration = ~7 days (weekly SC dosing)<ref name="ozempic-label"/> · ~24 h (oral)<ref name="rybelsus-label"/>

| halflife = ~165 hours (~1 week) — among the longest of any GLP-1 RA<ref name="lau2015"/>

| halflife = ~165 hours (~1 week), among the longest of any GLP-1 RA<ref name="lau2015"/>

| bioavailability = SC ~89%{{Citation needed}} · Oral ~0.4–1% (SNAC-enhanced)<ref name="rybelsus-label"/>

| pregnancy = Avoid. Discontinue ≥2 months before planned pregnancy due to long half-life. Animal data show embryofetal harm.<ref name="ozempic-label"/> Not contraceptive — but rapid weight loss + improved ovulation may unmask fertility in [[PCOS]].{{Citation needed}}

| pregnancy = Avoid. Discontinue ≥2 months before planned pregnancy due to long half-life. Animal data show embryofetal harm.<ref name="ozempic-label"/> Not contraceptive, but rapid weight loss + improved ovulation may unmask fertility in [[PCOS]].{{Citation needed}}

| legal = Rx-only;<ref name="ozempic-label"/> not a controlled substance

| intro = Semaglutide is a long-acting [[GLP-1 receptor agonist]] developed by [[Novo Nordisk]], marketed as '''[[Ozempic]]''' (weekly subcutaneous, for [[type 2 diabetes mellitus]]),<ref name="ozempic-label"/> '''[[Wegovy]]''' (weekly subcutaneous, for [[obesity]], [[cardiovascular risk reduction]] in obesity without diabetes, and [[MASH]] with fibrosis),<ref name="wegovy-label"/><ref name="select">Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). ''NEJM'' 389:2221–32. doi:10.1056/NEJMoa2307563</ref><ref name="essence">Newsome PN et al. (2025). Semaglutide in MASH (ESSENCE). FDA approval basis. {{Citation needed}}</ref> and '''[[Rybelsus]]''' (daily oral tablet, for T2DM).<ref name="rybelsus-label"/> It is, by revenue, among the highest-grossing medicines on the planet as of 2024.{{Citation needed}}

Line 20:

Line 22:

Semaglutide is the second weekly GLP-1 RA from Novo Nordisk's incretin program (after [[liraglutide]])<ref name="lau2015"/> and the molecule that, more than any other, made obesity treatment a mainstream rather than a specialty intervention.{{Citation needed}}

| pharmacokinetics = Acylation with a C18 fatty diacid drives non-covalent binding to serum albumin, slowing renal clearance and DPP-4 access. The Aib8 substitution renders the peptide DPP-4-resistant. Resulting terminal half-life ~165 h means once-weekly subcutaneous dosing produces near-steady-state plasma levels.<ref name="lau2015"/>

| pharmacokinetics = '''Chemistry'''. 31-amino-acid acylated peptide analog of human [[GLP-1]] (7–37), with Aib substitution at position 8 (blocks DPP-4 cleavage) and a C18 fatty diacid linked via γGlu-2×OEG spacer at Lys26 (drives albumin binding → ~165 h half-life)<ref name="lau2015">Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. ''J Med Chem'' 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726</ref>

Acylation with a C18 fatty diacid drives non-covalent binding to serum albumin, slowing renal clearance and DPP-4 access. The Aib8 substitution renders the peptide DPP-4-resistant. Resulting terminal half-life ~165 h means once-weekly subcutaneous dosing produces near-steady-state plasma levels.<ref name="lau2015"/>

Oral semaglutide (Rybelsus) is co-formulated with '''SNAC''' (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently raises gastric pH and protects the peptide locally — yielding ~0.4–1% bioavailability, which is sufficient at 14 mg daily to match Ozempic 0.5 mg weekly for glycemic effect (but not for weight loss).<ref name="rybelsus-label"/><ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. ''Sci Transl Med'' 10(467):eaar7047. doi:10.1126/scitranslmed.aar7047</ref> Strict fasting administration is mandatory; any concurrent food or beverage destroys absorption.<ref name="rybelsus-label"/>

Oral semaglutide (Rybelsus) is co-formulated with '''SNAC''' (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently raises gastric pH and protects the peptide locally, yielding ~0.4–1% bioavailability, which is sufficient at 14 mg daily to match Ozempic 0.5 mg weekly for glycemic effect (but not for weight loss).<ref name="rybelsus-label"/><ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. ''Sci Transl Med'' 10(467):eaar7047. doi:10.1126/scitranslmed.aar7047</ref> Strict fasting administration is mandatory; any concurrent food or beverage destroys absorption.<ref name="rybelsus-label"/>

Predominantly catabolic clearance via proteolysis; renal and hepatic impairment do not require dose adjustment.<ref name="ozempic-label"/> No CYP-mediated metabolism, so the interaction profile is dominated by ''gastric emptying'' effects on other oral medicines, not pharmacokinetic competition.<ref name="ozempic-label"/>

| pharmacodynamics = At maintenance doses semaglutide produces:

| pharmacodynamics = '''Receptor pharmacology'''. Selective long-acting agonist of the [[GLP-1 receptor]] (class B GPCR). Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and direct cardiovascular and renal protective effects.<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351. doi:10.1016/j.molmet.2021.101351</ref>

At maintenance doses semaglutide produces:

* HbA1c reduction of ~1.5–2.0 percentage points (Ozempic 1 mg)<ref name="sustain6">Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). ''NEJM'' 375:1834–44. doi:10.1056/NEJMoa1607141</ref>

* Weight loss of ~6 kg (Ozempic 1 mg, T2DM)<ref name="sustain6"/> to ~14.9% body weight (Wegovy 2.4 mg, obesity without T2DM, STEP-1)<ref name="step1"/>

Line 34:

Line 40:

* 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)<ref name="flow">Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). ''NEJM'' 391:109. doi:10.1056/NEJMoa2403347</ref>

| indications = <~~indication~~ ref="diabetes-type-2" author="MDElliottMD"/>

| indications = <problem ref="diabetes-type-2" author="MDElliottMD"/>

<~~indication~~ ref="obesity" author="MDElliottMD"/>

<~~indication~~ ref="cv-risk-obesity" author="MDElliottMD"/>

<~~indication~~ ref="mash-fibrosis" author="MDElliottMD"/>

<~~indication~~ ref="ckd-t2dm" author="MDElliottMD"/>

| dosing = <titration slug="ozempic-standard" author="MDElliottMD" title="Ozempic — standard T2DM titration">

| dosing = <titration slug="ozempic-standard" author="MDElliottMD" title="Ozempic, standard T2DM titration">

0.25 mg SC weekly × 4 weeks (non-therapeutic; tolerance ramp only)

→ 0.5 mg SC weekly × ≥4 weeks

Line 46:

Line 52:

→ 2 mg SC weekly (max) if needed<ref name="ozempic-label"/>

Slower titration is reasonable in any patient with significant GI symptoms — holding at a tolerated dose for 8–12 weeks before advancing is standard practice.

Slower titration is reasonable in any patient with significant GI symptoms, holding at a tolerated dose for 8–12 weeks before advancing is standard practice.

</titration>

0.25 mg SC weekly × 4 weeks

→ 0.5 mg × 4 weeks

Line 59:

Line 65:

</titration>

3 mg PO daily × 30 days (non-therapeutic ramp)

→ 7 mg PO daily × ≥30 days

Line 68:

Line 74:

| effects = Subjective effects vary considerably with dose and titration speed but reliably include:

* '''Early satiety''' — meals feel "complete" at a fraction of prior intake<ref name="step1"/>

* '''Early satiety''', meals feel "complete" at a fraction of prior intake<ref name="step1"/>

* '''Food noise quieting''' — the most commonly volunteered subjective change. Patients report that intrusive food-related thoughts simply stop.{{Citation needed}}

* '''Food noise quieting''', the most commonly volunteered subjective change. Patients report that intrusive food-related thoughts simply stop.{{Citation needed}}

* '''Reduced alcohol craving''' — corroborated by observational and small RCT data; mechanism likely shared with food reward circuitry<ref name="wang2024">Wang W, Volkow ND, Berger NA et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. ''Nat Commun'' 15:4548. doi:10.1038/s41467-024-48780-6</ref>

* '''Reduced alcohol craving''', corroborated by observational and small RCT data; mechanism likely shared with food reward circuitry<ref name="wang2024">Wang W, Volkow ND, Berger NA et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. ''Nat Commun'' 15:4548. doi:10.1038/s41467-024-48780-6</ref>

* '''Nausea''' — dose-dependent, worst in first 1–2 weeks of any new dose level<ref name="ozempic-label"/>

* '''Nausea''', dose-dependent, worst in first 1–2 weeks of any new dose level<ref name="ozempic-label"/>

* '''Constipation or diarrhea''' (variable, can alternate)<ref name="ozempic-label"/>

* '''Sulfurous eructation''' (a small but very real subgroup){{Citation needed}}

Line 84:

Line 90:

Importantly: semaglutide is '''not a contraceptive''', and the medicine may '''restore ovulation''' in patients with [[PCOS]] or [[obesity]]-associated anovulation.{{Citation needed}} Patients of childbearing potential should be counseled about contraception ''before'' starting.

| monitoring = * Baseline: HbA1c, weight, BP, renal function, lipid panel, [[ALT]]/AST (especially for MASH ~~indication~~)

| monitoring = * Baseline: HbA1c, weight, BP, renal function, lipid panel, [[ALT]]/AST (especially for MASH problem)

* Personal or family history of MTC or [[MEN2]] — '''contraindicated''', do not start<ref name="ozempic-label"/>

* Personal or family history of MTC or [[MEN2]], '''contraindicated''', do not start<ref name="ozempic-label"/>

* Every 3 months for first year: HbA1c, weight, GI tolerability, signs of [[pancreatitis]] or [[gallbladder disease]]

* Annual: renal function, lipids

Line 93:

Line 99:

* Inject SC in abdomen, thigh, or upper arm; rotate sites. Pen is single-patient, multi-dose.<ref name="ozempic-label"/>

* GI side effects almost always peak in first 2–4 weeks of any new dose level, then attenuate.<ref name="ozempic-label"/>

* Eat smaller portions earlier in the day. Plate sizes will feel comically large after a few weeks — that is the medicine working, not a problem to fix.

* Eat smaller portions earlier in the day. Plate sizes will feel comically large after a few weeks, that is the medicine working, not a problem to fix.

* Hydrate aggressively (volume depletion → AKI is a real risk).<ref name="ozempic-label"/>

* Resistance training during weight loss protects lean mass and is strongly encouraged.{{Citation needed}}

Line 111:

Line 117:

}}

~~[[Category:MedCategory]]~~

[[Category:GLP-1 receptor agonists]]

[[Category:Antidiabetic medicines]]

[[Category:Anti-obesity medicines]]

[[Category:Novo Nordisk medicines]]

MDElliottMD (talk | contribs)